Skip to content
x.com· @ · X·· 2026-04-23Score60
Body

@AACR Top Trials from Day 5
RMC-6236-001 | NCT06445062 | CLOVER | MYTHIC | CAR-PRISM | NCI-2018-01297 | CTEP 10355 | NCT05714072 | TROPIKANA | ZWI-ZW191-101 |
#AACR #AACR26 #AACR2026 #Cancer #Oncology #OncologyEvents #CancerResearch #OncTwitter #MedTwitter #MedX #LARVOL

Heat 1 · 1 like · 0 replies · 0 reposts

Conference abstracts
LB407NCT05379985NCT06445062matched by NCT NCT06445062
Daraxonrasib plus chemotherapy (CT) as first-line (1L) treatment for patients (Pts) with metastatic pancreatic adenocarcinoma (mPDAC)

Brian M. Wolpin, Benjamin L. Musher, Gulam A. Manji, Wungki Park, Alexander Spira, Nilofer Azad, Vaia Florou, Tiago Biachi De Castria, Mark H. O'Hara, Erkut Borazanci, Aparna Parikh, John Strickler, Joel Randolph Hecht, Shubham Pant, Shiraj Sen, E. Gabriela Chiorean, W. Clay Gustafson, Hina Patel, Vidya Seshadri, Yan Zheng, Davendra Sohal

Read the abstract →

Source: x.com · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org